查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1931187

乳房切片耗材市場（依產品類型、影像技術、最終用戶和應用分類）－全球預測，2026-2032年

Breast Biopsy Consumable Market by Product Type, Imaging Technique, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年乳房切片耗材市場價值為 6.2199 億美元，預計到 2026 年將成長至 6.596 億美元，年複合成長率為 6.96%，到 ​​2032 年將達到 9.9652 億美元。

關鍵市場統計數據
基準年 2025 6.2199億美元
預計年份：2026年 6.596億美元
預測年份 2032 9.9652億美元
複合年成長率 (%) 6.96%

現代醫療保健中影響乳房切片耗材決策的臨床、技術和採購促進因素的綜合框架

乳房切片耗材產業處於診斷準確性和以患者為中心的護理的關鍵交匯點。新的影像技術、改進的醫療設備人體工學以及不斷發展的臨床路徑正在共同重塑組織採集的方式。臨床醫生和採購團隊越來越重視能夠縮短手術時間、提高檢體充足率和最大限度減少患者不適的工具，而醫療機構管理者在選擇設備時則需要在營運效率和安全要求之間取得平衡。

影像技術的整合、設備創新、日益嚴格的監管以及患者體驗的提升，正在推動變革性變化，並重新定義競爭格局。

乳房切片耗材市場格局正受到多項重大變革的影響，這些變革正在重塑臨床實踐和供應鏈的優先事項。首先，成像技術的進步正在加速跨模態相容性的發展。曾經針對單一模態最佳化的設備，如今正被改造以在超音波、立體定位和磁振造影等多種環境下可靠運作。這種轉變正在推動籌資策略優先選擇能夠在多種手術環境下保持性能穩定的設備。

美國近期推出的關稅措施正在推動整個價值鏈進行供應鏈重組、採購多元化和採購韌性提升。

近期美國貿易政策引發的關稅變動，為依賴全球供應鏈的乳房切片耗材生產商和經銷商帶來了新的挑戰。關稅調整影響了進口零件和成品的到岸成本結構，促使企業重新評估其籌資策略、供應商關係和庫存模式。為此，許多企業正在進行敏感度分析，以確定哪些零件最易受關稅風險影響，以及哪些生產過程可以轉移到其他地區。

透過細分分析洞察，將產品類型、影像方式、醫療環境和臨床應用聯繫起來，從而幫助制定有針對性的商業和臨床策略。

細分分析揭示了不同產品類型、影像方式、最終用戶和臨床應用領域中截然不同的應用趨勢。產品細分包括切片檢查盒、取芯針、彈簧式裝置和真空抽吸針，其中取芯針又細分為 14G、16G 和 18G 三種規格。這些細分反映了臨床醫生對檢體大小、操作控制和與影像技術相容性的偏好。當組織學保真度至關重要時，通常會選擇用於較大直徑取芯的裝置；而較小規格的裝置則更適用於微創手術和門診流程。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢將影響採用模式、監管協調和商業化方法。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的產品應用、監管預期和採購慣例均有顯著影響。在美洲，私人和公共支付方、已建立的診斷網路以及對門診手術效率的高度重視等因素影響著決策，從而推動了兼顧臨床性能和運營效率的設備的普及。該地區報銷框架和臨床指南的更新也推動了對能夠提供可重複診斷樣本的解決方案的需求。

競爭格局的特點是透過產品創新、證據累積、整合服務模式和穩健的供應鏈實現長期差異化。

乳房切片耗材領域的競爭格局體現了技術創新、臨床證據累積和策略合作的融合。主要企業正致力於產品迭代改進，以提高檢體品質和手術效率，同時拓展培訓和服務範圍，確保臨床信心。與影像平台供應商的合作以及與診斷工作流程的整合正成為關鍵的差異化因素，因為收購方優先考慮能夠無縫支援現有影像模式工作流程的設備。

領導企業導向的實用策略藍圖：整合跨模式產品創新、供應鏈韌性、證據產生和靈活的商業模式

為了充分利用不斷變化的臨床需求和供應鏈現狀，產業領導者應攜手採取一系列策略行動，協調產品開發、商業性執行和營運韌性。首先，透過在產品藍圖中優先考慮跨模態相容性，並確保設備能夠在磁振造影 (MRI)、立體定位和超音波環境下正常運行，來擴大目標臨床使用者群體並簡化採購決策。將設計創新與和臨床醫生共同開發的舉措相結合，以加速產品推廣應用並確保其在實際應用中的有效性。

嚴謹的混合方法研究設計，整合了臨床文獻、專家訪談、工具性分析和供應鏈診斷，以得出檢驗的研究結果。

本分析的研究結合了系統性文獻綜述、專家訪談、設備規格分析和供應鏈評估，旨在得出切實可行的見解。同行評審的臨床文獻和監管申報文件為理解設備安全性和手術結果奠定了基礎，同時對技術規格進行了評估，以確定其在不同顯像模式和臨床工作流程中的兼容性。此外，還對介入放射科醫生、乳房外科醫生、採購人員和設備管理人員進行了平行訪談，從而揭示了設備選擇和操作限制的實際考慮因素。

臨床、營運和監管動態的整合，定義了該領域持續競爭優勢的策略要務。

乳房切片耗材產業正向性能主導市場轉型，設備選擇主要取決於臨床結果、模式相容性和操作效率。針頭設計、真空輔助功能和人體工學設計的創新，正滿足對可重複檢體品質和改善病患體驗的需求。同時，貿易政策變化和監管預期等外部壓力，也促使各機構優先考慮供應鏈透明度和基於實證醫學的選擇標準。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章乳房切片耗材市場（依產品類型分類）

  • 切片檢查盒
  • 芯針
    • 14G
    • 16G
    • 18G
  • 彈簧加載裝置
  • 吸輔助針

第9章乳房切片耗材市場（依診斷影像技術分類）

  • 磁共振引導
  • 立體定位
  • 超音波引導

第10章 依最終用戶分類的乳房切片耗材市場

  • 門診手術中心
  • 診斷中心
  • 醫院

第11章 依應用分類的乳房切片耗材市場

  • 癌症檢測
  • 囊腫穿刺
  • 纖維腺瘤的評估

第12章 各地區乳房切片耗材市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章乳房切片耗材市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國乳房切片耗材市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國乳房切片耗材市場

第16章 中國乳房切片耗材市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Biomedical Ltd.
  • Advanced Sterilization Products
  • AprioMed AB
  • Argon Medical Devices, Inc.
  • Becton, Dickinson and Company
  • Biomedical Polymers, Inc.
  • Biomedical Srl
  • BIP Biomed. Inst. & Prod. GmbH
  • CR Bard, Inc.
  • Cardinal Health, Inc.
  • CP Medical
  • Devicor Medical Products, Inc.
  • GALLINI Srl
  • Hologic, Inc.
  • INRAD, Inc.
  • Integra LifeSciences Holdings Corporation
  • Labtician Ophthalmics, Inc.
  • Merit Medical Systems, Inc.
  • Ranfac Corp.
  • SOMATEX Medical Technologies GmbH
  • STERYLAB Srl
  • Sterylab Srl
  • Teleflex Incorporated
  • Tsunami Srl
Product Code: MRR-7B550E008DA7

The Breast Biopsy Consumable Market was valued at USD 621.99 million in 2025 and is projected to grow to USD 659.60 million in 2026, with a CAGR of 6.96%, reaching USD 996.52 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 621.99 million
Estimated Year [2026] USD 659.60 million
Forecast Year [2032] USD 996.52 million
CAGR (%) 6.96%

Comprehensive framing of clinical, technological, and procurement drivers shaping decision-making for breast biopsy consumables in modern healthcare

The breast biopsy consumable sector occupies a critical position at the intersection of diagnostic precision and patient-centered care. New imaging capabilities, refinements in device ergonomics, and evolving clinical pathways are collectively reshaping how tissue sampling is performed. Clinicians and procurement teams increasingly prioritize tools that reduce procedural time, improve specimen adequacy, and minimize patient discomfort, while healthcare administrators weigh device selection against operational efficiency and safety requirements.

Against this backdrop, the ecosystem supporting breast biopsy consumables encompasses product manufacturers, imaging providers, hospitals, diagnostic centers, and ambulatory surgical settings. Technological convergence is apparent: needle design, vacuum assistance, and spring-loaded mechanisms are being optimized to integrate with ultrasound, stereotactic, and MRI-guided workflows. As a result, adoption dynamics are driven not only by device-level performance but also by modality compatibility, reimbursement pathways, and the need for standardized clinical protocols that support reproducible outcomes.

Understanding this environment requires a nuanced view of clinical utility, procurement decision drivers, and regulatory oversight. This report synthesizes those elements, emphasising actionable intelligence for clinical leaders, product developers, and institutional buyers to align investments with evolving standards of care and patient expectations.

Transformative shifts driven by imaging convergence, device innovation, regulatory rigor, and patient experience that redefine competitive priorities

The landscape for breast biopsy consumables is being transformed by several high-impact shifts that reconfigure clinical practice and supply chain priorities. First, imaging-driven refinements are accelerating cross-modal compatibility; devices once optimized for a single modality are now being adapted to perform reliably across ultrasound, stereotactic, and MRI settings. This transition encourages procurement strategies that favour devices delivering consistent performance across multiple procedural contexts.

Second, clinician preference is moving toward devices that provide both procedural efficiency and superior specimen quality. Innovations in needle geometry, vacuum-assisted extraction, and spring-loaded mechanisms are reducing the need for repeat procedures and improving diagnostic confidence. Consequently, hospitals and diagnostic centers are investing in devices that reduce downstream costs associated with inconclusive samples and repeat visits.

Third, regulatory scrutiny and quality standards continue to raise the bar for device validation and post-market surveillance. Manufacturers must demonstrate robust clinical evidence, comprehensive training programs, and traceability across supply chains to meet institutional purchasing criteria. Finally, a stronger emphasis on patient experience-driven by patient advocacy and value-based care models-is influencing device selection, with an eye toward minimally invasive options that shorten recovery and support outpatient care pathways. These converging forces are creating a more integrated, performance-led marketplace where clinical outcomes and operational efficiency are mutually reinforcing.

How recent United States tariff actions are prompting supply chain redesigns, sourcing diversification, and procurement resilience measures across the value chain

Recent tariff developments originating from United States trade policy have introduced new layers of complexity for manufacturers and distributors of breast biopsy consumables that rely on global supply chains. Tariff adjustments affect the landed cost structure of imported components and finished devices, encouraging firms to reassess sourcing strategies, supplier relationships, and inventory models. In response, many organizations are conducting sensitivity analyses to determine which components are most exposed to tariff risk and which production steps can be reallocated to alternative jurisdictions.

These trade measures also prompt strategic recalibrations in contract negotiations and pricing strategies. Suppliers are increasingly transparent about origin of manufacture and are layering contractual protections to manage cost volatility. Procurement teams, in turn, are seeking longer lead times and flexible procurement terms to mitigate the risk of sudden cost shifts. The cumulative impact of tariff policy is not limited to direct procurement costs; it affects clinical deployment timelines when manufacturers adjust manufacturing footprints or reroute logistics to avoid tariff exposure.

Moreover, tariff-driven supply chain reconfigurations heighten the importance of supplier diversification and nearshoring as tools to improve resilience. Healthcare providers and device companies that invest in supply chain visibility, inventory buffers, and strategic supplier partnerships will be better positioned to ensure uninterrupted access to essential consumables. Transitional strategies that prioritize continuity of care while managing cost pressures are essential in this evolving trade environment.

Segment-driven insights linking product types, imaging modalities, care settings, and clinical uses to inform targeted commercial and clinical strategies

Segmentation analysis reveals differentiated adoption dynamics across product types, imaging modalities, end users, and clinical applications. Product segmentation distinguishes Biopsy Kit, Core Needle, Spring Loaded Device, and Vacuum Assisted Needle, with the Core Needle further detailed as 14G, 16G, and 18G variants; these distinctions map to clinician preferences for sample size, procedural control, and compatibility with imaging techniques. Devices designed for larger core diameters are often chosen when histological fidelity is paramount, whereas finer gauges support minimally invasive approaches and outpatient workflows.

Imaging technique segmentation-MRI Guided, Stereotactic, and Ultrasound Guided-shapes device design and procurement decisions. MRI-guided procedures demand materials and device constructs compatible with magnetic environments and extended procedural times, while stereotactic approaches emphasize spatial precision within mammography suites. Ultrasound-guided workflows prioritize real-time visualization and device ergonomics that support rapid tissue targeting. Each modality therefore influences the prioritized device attributes and the training required for safe and effective use.

End user segmentation including Ambulatory Surgical Centers, Diagnostic Centers, and Hospitals highlights divergent procurement drivers and operational constraints. Ambulatory settings pursue devices that enable short procedures and rapid turnover, diagnostic centers focus on throughput and repeatability, and hospitals require versatility across inpatient and outpatient contexts. Application segmentation spanning Cancer Detection, Cyst Aspiration, and Fibroadenoma Evaluation clarifies clinical indications that determine device selection, specimen handling protocols, and follow-up pathways. Understanding how these segments intersect provides a nuanced lens for product positioning, clinician training, and commercialization planning.

Regional dynamics across Americas, Europe Middle East & Africa, and Asia-Pacific that dictate adoption patterns, regulatory alignment, and commercialization approaches

Regional dynamics exert a pronounced influence on product adoption, regulatory expectations, and procurement practices across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, decisions are shaped by a mix of private and public payers, well-established diagnostic networks, and a strong focus on outpatient procedural efficiency; these factors promote adoption of devices that balance clinical performance with operational throughput. Reimbursement frameworks and clinical guideline updates in the region also drive demand for solutions that deliver reproducible diagnostic samples.

In Europe, Middle East & Africa, regulatory harmonization, local clinical practices, and varying infrastructure capacity yield heterogeneous adoption patterns. In some markets within this region, centralized hospital systems and national procurement programs favour standardization and long-term supplier partnerships, whereas other markets prioritise flexibility and local manufacturing partnerships. Asia-Pacific displays rapid technology adoption in urban tertiary centres alongside an expanding footprint of ambulatory and diagnostic facilities; this divergence creates opportunities for scalable devices that can be adapted for both high-volume metropolitan hospitals and resource-conscious outpatient clinics.

Across all regions, manufacturers and distributors must align commercialization strategies with local regulatory requirements, clinician training expectations, and healthcare delivery models. Regional market entrants that tailor value propositions to local care pathways and payer landscapes will be better able to secure clinician endorsement and institutional adoption.

Competitive landscape characterized by product innovation, evidence generation, integrated service models, and supply chain robustness driving long-term differentiation

Competitive activity in the breast biopsy consumable space reflects a blend of technical innovation, clinical evidence generation, and strategic partnerships. Leading firms are investing in iterative product enhancements that improve specimen quality and procedural ergonomics while expanding training and service offerings to secure clinical trust. Partnerships with imaging platform providers and integration into diagnostic workflows are becoming key differentiators as buyers prioritise devices that seamlessly support established modality workflows.

In addition to product features, market positioning increasingly rests on post-market support, training programs, and evidence generation. Organizations that invest in multicentre clinical studies, peer-reviewed publications, and robust clinician education demonstrate higher levels of institutional acceptance. Distribution and service networks also play an outsized role: rapid access to consumables, spare parts, and local technical assistance can determine whether a device is preferred for high-volume settings.

Emerging competitors often target niche applications or seek to undercut incumbents through price competitiveness, but sustainable advantage tends to accrue to companies that combine product reliability with comprehensive clinical support and supply chain resilience. For stakeholders evaluating partners or acquisition targets, attention to regulatory histories, quality systems, and evidence portfolios provides valuable insight into long-term viability.

Actionable strategic roadmap for leaders to integrate cross-modal product innovation, supply chain resilience, evidence generation, and flexible commercial models

To capitalise on shifting clinical needs and supply chain realities, industry leaders should adopt a coordinated set of strategic actions that align product development, commercial execution, and operational resilience. First, prioritize cross-modal compatibility in product roadmaps so devices function reliably across MRI, stereotactic, and ultrasound environments, thereby broadening the addressable clinical base and simplifying procurement decisions. Coupling design innovation with clinician co-creation initiatives will accelerate adoption and ensure real-world usability.

Second, strengthen supplier diversification and nearshoring options to reduce exposure to tariff and logistics volatility. Establishing transparent supplier scorecards and contingency sourcing protocols will improve operational continuity. Third, invest in rigorous clinical evidence and education programs that demonstrate procedural efficiency, specimen adequacy, and patient experience benefits; such evidence supports procurement discussions and reimbursement engagement. Fourth, develop flexible commercial models that accommodate ambulatory surgical centers, diagnostic centers, and hospitals through tailored service bundles, training, and inventory solutions.

Finally, embed digital enablement in product and service offerings by providing procedural analytics, training platforms, and inventory management tools that reinforce device value propositions. Leaders who integrate clinical performance, supply chain resilience, and supportive services will differentiate in a marketplace increasingly defined by outcomes and operational efficiency.

Rigorous mixed-methods research design integrating clinical literature, expert interviews, device analysis, and supply chain diagnostics for validated insights

The research underpinning this analysis combined systematic literature review, expert interviews, device specification analysis, and supply chain diagnostics to generate actionable insights. Peer-reviewed clinical literature and regulatory filings provided a foundation for understanding device safety profiles and procedural outcomes, while technical specifications were evaluated to map compatibility across imaging modalities and clinical workflows. In parallel, interviews with interventional radiologists, breast surgeons, procurement leads, and device managers informed practical considerations around device selection and operational constraints.

A supply chain diagnostic approach assessed sourcing dependencies, logistics pathways, and tariff exposure to identify vulnerability points and potential mitigation strategies. Competitive profiling drew on product portfolios, clinical evidence, and service capabilities to assess differentiation and positioning. The methodology emphasized triangulation across sources so that conclusions are anchored in convergent evidence rather than single data points. Throughout, data validation steps including expert review and cross-checking against technical documentation were applied to ensure analytical rigor and reliability of insights.

Synthesis of clinical, operational, and regulatory dynamics that define strategic imperatives for sustainable competitive advantage in the sector

The breast biopsy consumable domain is evolving into a performance-driven market where device selection is governed by clinical outcomes, modality compatibility, and operational efficiency. Innovations in needle design, vacuum assistance, and ergonomics are aligning with demands for reproducible specimen quality and enhanced patient experience. At the same time, external pressures including trade policy shifts and regulatory expectations are prompting organizations to prioritize supply chain transparency and evidence-based selection criteria.

Stakeholders who align product development with clinician needs, invest in robust clinical validation, and embed resilient sourcing strategies will be best positioned to influence care pathways and procurement decisions. Additionally, a focus on scalable training and service models will accelerate adoption across diverse care settings from ambulatory centers to tertiary hospitals. Ultimately, sustainable competitive advantage in this sector will accrue to organizations that demonstrate measurable clinical value and deliver consistent operational support that integrates seamlessly into established diagnostic workflows.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Biopsy Consumable Market, by Product Type

  • 8.1. Biopsy Kit
  • 8.2. Core Needle
    • 8.2.1. 14G
    • 8.2.2. 16G
    • 8.2.3. 18G
  • 8.3. Spring Loaded Device
  • 8.4. Vacuum Assisted Needle

9. Breast Biopsy Consumable Market, by Imaging Technique

  • 9.1. MRI Guided
  • 9.2. Stereotactic
  • 9.3. Ultrasound Guided

10. Breast Biopsy Consumable Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Diagnostic Centers
  • 10.3. Hospitals

11. Breast Biopsy Consumable Market, by Application

  • 11.1. Cancer Detection
  • 11.2. Cyst Aspiration
  • 11.3. Fibroadenoma Evaluation

12. Breast Biopsy Consumable Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Breast Biopsy Consumable Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Breast Biopsy Consumable Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Breast Biopsy Consumable Market

16. China Breast Biopsy Consumable Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Biomedical Ltd.
  • 17.6. Advanced Sterilization Products
  • 17.7. AprioMed AB
  • 17.8. Argon Medical Devices, Inc.
  • 17.9. Becton, Dickinson and Company
  • 17.10. Biomedical Polymers, Inc.
  • 17.11. Biomedical Srl
  • 17.12. BIP Biomed. Inst. & Prod. GmbH
  • 17.13. C. R. Bard, Inc.
  • 17.14. Cardinal Health, Inc.
  • 17.15. CP Medical
  • 17.16. Devicor Medical Products, Inc.
  • 17.17. GALLINI S.r.l.
  • 17.18. Hologic, Inc.
  • 17.19. INRAD, Inc.
  • 17.20. Integra LifeSciences Holdings Corporation
  • 17.21. Labtician Ophthalmics, Inc.
  • 17.22. Merit Medical Systems, Inc.
  • 17.23. Ranfac Corp.
  • 17.24. SOMATEX Medical Technologies GmbH
  • 17.25. STERYLAB S.r.l.
  • 17.26. Sterylab S.r.l.
  • 17.27. Teleflex Incorporated
  • 17.28. Tsunami S.r.l.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BREAST BIOPSY CONSUMABLE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY BIOPSY KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY BIOPSY KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY BIOPSY KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 14G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 14G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 14G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 16G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 16G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 16G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 18G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 18G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 18G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SPRING LOADED DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SPRING LOADED DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SPRING LOADED DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY VACUUM ASSISTED NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY VACUUM ASSISTED NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY VACUUM ASSISTED NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY MRI GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY MRI GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY MRI GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY STEREOTACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY STEREOTACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY STEREOTACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY ULTRASOUND GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY ULTRASOUND GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY ULTRASOUND GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CANCER DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CANCER DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CANCER DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CYST ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CYST ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CYST ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY FIBROADENOMA EVALUATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY FIBROADENOMA EVALUATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY FIBROADENOMA EVALUATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 132. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 133. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)